2015至2022年5岁以下儿童呼吸道合胞病毒住院疾病负担
这项回顾性队列研究纳入美国10个地区50家儿童医院2015年6月1日至2023年3月31日就诊的5岁以下RSV或毛细支气管炎患儿924061例,中位年龄8月龄,58.0%为男性。其中348077例(37.7%)诊断为RSV,187850例(54.0%)住院。与2015至2019年相比,2021和2022年各年龄段住院发病率比均升高,24至59月龄儿童2022年住院可能性为2015至2019年的4.86倍(95%CI 4.75-4.98),0至5月龄婴儿为1.77倍(95%CI 1.74-1.80)。无论年份,使用Medicaid的患儿比未使用者更易住院。作者认为RSV住院使用增加可能部分源于检测增加。
要点
- 2022年24至59月龄儿童RSV住院可能性为2015至2019年的4.86倍(95%CI 4.75-4.98),0至5月龄婴儿为1.77倍(95%CI 1.74-1.80)。
- 2021和2022年各年龄段RSV住院发病率比均较2015至2019年升高。
- 无论年份,使用Medicaid的患儿比未使用者更可能住院。
- 2021和2022年RSV与毛细支气管炎住院呈非典型季节性,RSV就诊总体增加,毛细支气管炎住院减少或与既往季节持平。
- 作者认为观察到的RSV住院使用增加可能部分源于检测增加。
适用人群与场景
- 美国10个地理区域50家儿童医院中,2015年6月1日至2023年3月31日在重症监护、住院、急诊或观察单元就诊的5岁以下RSV和毛细支气管炎患儿。
研究设计与关键结果
- 回顾性队列研究,纳入924061例参与者,中位年龄8月龄(IQR 5-16),535619例(58.0%)为男性;348077例(37.7%)诊断为RSV,其中187850例(54.0%)住院。
- 2021和2022年各年龄段住院发病率比均较2015至2019年升高;24至59月龄儿童2022年住院可能性为2015至2019年的4.86倍(95%CI 4.75-4.98),0至5月龄婴儿为1.77倍(95%CI 1.74-1.80)。
- 无论年份,使用Medicaid的患儿比未使用者更可能住院。
- 2021和2022年RSV与毛细支气管炎住院呈非典型季节性,RSV就诊总体增加;大流行后各年龄段RSV住院增加,尤其年长儿童,而毛细支气管炎住院较既往季节减少或持平。
- 作者认为观察到的RSV住院使用增加可能部分源于检测增加。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为观察到的RSV住院使用增加可能部分源于检测增加,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Respiratory syncytial virus (RSV) resurgences have been noted following the COVID-19 pandemic in many countries. Recent findings suggest that the 2021 and 2022 RSV seasons were more severe than in past seasons, and age distribution may have shifted toward older children in the younger than 5 years age group.
OBJECTIVES: To estimate age-specific changes in RSV hospital-based burden of disease before and after the COVID-19 pandemic and to compare incidence by Medicaid use.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included children younger than 5 years diagnosed with RSV and bronchiolitis at 50 US children's hospitals in 10 US geographic regions. The included participants had an encounter in intensive care, inpatient, emergency, or observational units, between June 1, 2015, and March 31, 2023.
EXPOSURES: Diagnosis of RSV, bronchiolitis, or both at encounter.
MAIN OUTCOME AND MEASURES: Incidence rate ratio of hospital use within each care unit before vs after the COVID-19 pandemic. It was hypothesized a priori that incidence of hospital use would increase overall in 2021 and 2022 compared with 2015 to 2019 and that the increase would be greater among children 12 months and older.
RESULTS: Of 924 061 study participants (median [IQR] age, 8 (5-16) months; 535 619 [58.0%] male), 348 077 (37.7%) were diagnosed with RSV. Of these, 187 850 (54.0%) were hospitalized. Incidence rate ratios of hospitalization increased for all ages in 2021 and 2022 compared with 2015 to 2019. Children aged 24 to 59 months were 4.86 (95% CI, 4.75-4.98) times as likely to be hospitalized in 2022 compared with 2015 to 2019, whereas infants aged 0 to 5 months were 1.77 (95% CI, 1.74-1.80) times as likely. Medicaid patients were more likely to be hospitalized than non-Medicaid patients regardless of year.
CONCLUSIONS AND RELEVANCE: Hospitalizations for RSV and bronchiolitis demonstrated atypical seasonality in 2021 and 2022, with an overall increase in RSV encounters. Postpandemic RSV hospitalization increased for all ages, but especially among older children, whereas bronchiolitis hospitalization was decreased or unchanged compared with earlier seasons. These findings suggest some of the observed increase in RSV hospital use may be due to increased testing.
参考来源
- Suss RJ, Simões EAF. Respiratory Syncytial Virus Hospital-Based Burden of Disease in Children Younger Than 5 Years, 2015-2022. JAMA Netw Open. 2024. PMID: 38635270. doi:10.1001/jamanetworkopen.2024.7125
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。